Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01489176 · ClinicalTrials.gov registry record · Phase 3
Regadenoson Real Time Perfusion Imaging Trial-Optison
A Phase 3 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT01489176 is a Phase 3 study that has completed, run by University of Nebraska. The registered enrollment target is 50 participants.
The verdict
NCT01489176, a Phase 3 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose if this study is to examine how effective Regadenoson is in detecting coronary artery disease during a stress echocardiogram when Optison is administered. Optison is a contrast agent that improves the images of the heart on the echocardiogram (echo) machine. Optison is approved by the Food and Drug Administration (FDA) to use during stress echocardiograms. Regadenoson is a commercially available rapid acting stress agent that is used to chemically increase the heart rate and is approved for nuclear imaging tests. Regadenoson is a FDA approved drug but not for the intended use in this study.
Interventions
- DRUG Regadenoson; Optison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-07-31 |
| Est. Completion | 2014-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01489176
The ClinicalTrials.gov registry entry for NCT01489176 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Regadenoson; Optison is the first listed.
NCT01489176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01489176 about?
NCT01489176 is a clinical study titled "Regadenoson Real Time Perfusion Imaging Trial-Optison". The purpose if this study is to examine how effective Regadenoson is in detecting coronary artery disease during a stress echocardiogram when Optison is administered. Optison is a contrast agent that improves the images of the heart on the echocardiogram (echo) machine. Optison is approved by the Fo...
What is the current status of trial NCT01489176?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2012-07-31. Estimated completion is 2014-12-01.
What interventions are being tested in trial NCT01489176?
The interventions under investigation include: Regadenoson; Optison (DRUG).
Who is sponsoring clinical trial NCT01489176?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.